Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia
- PDF / 860,764 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 69 Downloads / 161 Views
ORIGINAL RESEARCH ARTICLE
Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33‑Positive Acute Myeloid Leukemia Carla Mamolo1 · Verna Welch2 · Roland B. Walter3,4 · Joseph C. Cappelleri5 · James Brockbank6 · Matthew Cawson6 · Chris Knight6 · Michele Wilson7 Accepted: 29 October 2020 © The Author(s) 2020
Abstract Background Gemtuzumab ozogamicin (GO) was approved in 2017 in the US for the treatment of adults with newly diagnosed CD33-positive (CD33+) acute myeloid leukemia (AML), and adults and pediatric patients with CD33+ relapsed/ refractory (R/R) AML. Objective The aim of this study was to estimate the budgetary impact of introducing GO to a 1-million-member US health plan over a 5-year period. Methods We developed models to estimate the impact of introducing GO in combination with conventional induction chemotherapy or as monotherapy for newly diagnosed AML, and as monotherapy for R/R AML. Models were built using data on drug costs and treatment-related outcomes obtained from published clinical trials and other publicly available sources. Results were reported on a per member/per year and per member/per month (PMPM) basis. Results Base-case results of the newly diagnosed model indicated that the addition of GO in the combination setting reduced the overall budget of a 1-million-member health plan. The estimated net cost (US$) savings ranged from $72,969 ($0.006 PMPM) in year 1 to $745,426 ($0.062 PMPM) in year 5. In the monotherapy setting, GO was associated with increased net costs ranging from $4118 (0.0003 PMPM) in year 1 to $31,885 ($0.003 PMPM) in year 5. Base-case results of the R/R AML model demonstrated increased net costs that ranged from $17,326 ($0.001 PMPM) in year 1 to $46,163 ($0.004 PMPM) in year 5. Scenario analyses in all settings indicated the budget impact was not overly sensitive to the selected input assumptions, with the exception of the scenario considering only the pharmacy budget impact in the combination setting. Conclusions The introduction of GO for newly diagnosed and R/R AML would have a minimal impact on the budget of a US health plan and could result in cost savings in the combination therapy setting for newly diagnosed AML.
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40273-020-00976-6) contains supplementary material, which is available to authorized users. * Carla Mamolo [email protected] 1
Patient & Health Impact, Pfizer Inc, 445 Eastern Point Road, Groton, CT 06833, USA
2
Patient & Health Impact, Pfizer Inc, New York, NY, USA
3
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
4
Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA
5
Statistics, Pfizer Inc, Groton, CT, USA
6
RTI Health Solutions, Manchester, UK
7
RTI Health Solutions, Research Triangle Park, NC, USA
Key Points for Decision Makers Gemtuzumab ozogamicin (GO) was approved in 2017 in the US for the treatment of adults with newly
Data Loading...
